Suping Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suping Wang has a total of 302 co-authors. Here are the top co-authors by number of shared publications:
Yongliang Feng
36 shared publicationsTian Yao
28 shared publications- Yongliang Feng
School of Public Health, Shanxi Medical University
18 shared publications - Yawei Zhang
Department of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
15 shared publications Linying Gao
13 shared publicationsYandi Li
13 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Elsevier in SSRN Electronic Journal
Non-invasive miRNAs and risk of no response to hepatitis B vaccination in infants: a prospective cohort study
Background: Infants born to HBsAg-positive mothers who fail to respond to hepatitis B vaccine (hepB) are at high risk of HBV infection. We aimed to identify miRNAs in cord blood mononuclear cells (CBMCs) as non-invasive biomarkers for predicting no response to hepB.Method: This prospective cohort study enrolled 367 mother-neonate pairs. CBMCs were analyzed via miRNA sequencing (n=16) and validated by RT-qPCR (n=128). SMOTE was applied to address class imbalance. The impact of miRNAs on no response to hepB was assessed using multivariate regression, restricted cubic spline regression and subgroup analysis. Predictive models were constructed using random forest, XGBoost, SVM, logistic regression and compared through AUC, sensitivity, negative predictive value.Results: The miR-183-5p and miR-486-5p were upregulated in the no response group through miRNA sequencing and RT-qPCR. The elevated expression of miR-183-5p and miR-486-5p in CBMCs increased the risk of no response (adjusted OR = 1.26, 95% CI: 1.14~1.41; adjusted OR = 1.13, 95% CI: 1.02~1.26). MiR-183-5p and miR-486-5p were nonlinearly and positively associated with risk of no response (P nonlinear <0.05). The stronger associations of miR-183-5p and miR-486-5p with risk of no response were observed in mothers older than 30 years and in boys (P<0.05). A random forest prediction model for no response built using the above miRNAs, demographic and HBV infection characteristics achieved superior AUC (0.931), sensitivity (0.931), and negative predictive value (0.939).Conclusion: The miR-183-5p and miR-486-5p in CBMCs are promising non-invasive biomarkers for early identification of infants at risk of hepatitis B vaccine no response, especially those born to mothers aged over 30 years and male infants. A miRNA-based model provides a novel tool to screen these high-risk infants early.
- 25 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNon-invasive miRNAs and risk of no response to hepatitis B vaccination in infants: a prospective cohort study
Background: Infants born to HBsAg-positive mothers who fail to respond to hepatitis B vaccine (hepB) are at high risk of HBV infection. We aimed to identify miRNAs in cord blood mononuclear cells (CBMCs) as non-invasive biomarkers for predicting no response to hepB.Method: This prospective cohort study enrolled 367 mother-neonate pairs. CBMCs were analyzed via miRNA sequencing (n=16) and validated by RT-qPCR (n=128). SMOTE was applied to address class imbalance. The impact of miRNAs on no response to hepB was assessed using multivariate regression, restricted cubic spline regression and subgroup analysis. Predictive models were constructed using random forest, XGBoost, SVM, logistic regression and compared through AUC, sensitivity, negative predictive value.Results: The miR-183-5p and miR-486-5p were upregulated in the no response group through miRNA sequencing and RT-qPCR. The elevated expression of miR-183-5p and miR-486-5p in CBMCs increased the risk of no response (adjusted OR = 1.26, 95% CI: 1.14~1.41; adjusted OR = 1.13, 95% CI: 1.02~1.26). MiR-183-5p and miR-486-5p were nonlinearly and positively associated with risk of no response (P nonlinear <0.05). The stronger associations of miR-183-5p and miR-486-5p with risk of no response were observed in mothers older than 30 years and in boys (P<0.05). A random forest prediction model for no response built using the above miRNAs, demographic and HBV infection characteristics achieved superior AUC (0.931), sensitivity (0.931), and negative predictive value (0.939).Conclusion: The miR-183-5p and miR-486-5p in CBMCs are promising non-invasive biomarkers for early identification of infants at risk of hepatitis B vaccine no response, especially those born to mothers aged over 30 years and male infants. A miRNA-based model provides a novel tool to screen these high-risk infants early.
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Association between Early Adulthood BMI and Chronic Liver Disease: A Prospective Cohort Study of 0·5 Million Adults from the China Kadoorie Biobank
Background: In East Asian populations, evidence on the association between early adulthood body mass index (BMI) and later-life chronic liver diseases is scarce, with distinct lifestyle, genetic factors, fat distribution and hepatitis B virus (HBV) infection from Western populations. This study aimed to explore this association, examine the modifying effects of midlife healthy lifestyle factors (HLFs) and hepatitis B surface antigen (HBsAg) status on this association, and evaluate the mediating effect of midlife metabolic syndrome (MetS).Methods: This prospective cohort study utilized data from the China Kadoorie Biobank (CKB), enrolling adults aged 35–70 years free of baseline cancer or liver disease. A total of 387,541 participants from ten Chinese regions were included in the analysis. Primary outcomes were morbidity of chronic liver disease (CLD), metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD), which were obtained mainly through local disease and death registries and the national health insurance (HI) system. Weight at age 25, midlife lifestyle and HBsAg status were obtained from the CKB baseline survey. Cox proportional hazards models were applied to estimate the association between early adulthood BMI and later-life liver-related outcomes. Interaction analysis was performed to examine the modifying effects of midlife HLF and HBsAg status. The Bootstrap method was used to verify the mediation effect of MetS in the association under investigation.Findings: The baseline survey was conducted from 2004 to 2008. During a median follow-up of 12·1 years 5,983 (1·5%) incident CLD cases were documented. After adjustment for covariates, elevated early-adulthood BMI was associated with increased later-life CLD risk in a monotonic dose-response manner (P for trend 0·05), whereas HBsAg status exhibited a significant interaction with early adulthood BMI (P = 0·008), and in the HBsAg-negative group, later-life CLD risk was positively associated with early adulthood BMI. MetS-mediated effect was strongest for MASLD, the proportion mediated increased from 20·71% to 46·74% with rising BMI (all P < 0·001).Interpretation: This study confirms that higher BMI in early adulthood significantly increases the risk of later-life chronic liver diseases among Chinese adults, particularly in HBsAg-negative adults, regardless of subsequent lifestyle changes. These findings highlight the urgency for public health strategies to prevent overweight in young adulthood and to optimize the management of HBV infection.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAssociation between Early Adulthood BMI and Chronic Liver Disease: A Prospective Cohort Study of 0·5 Million Adults from the China Kadoorie Biobank
Background: In East Asian populations, evidence on the association between early adulthood body mass index (BMI) and later-life chronic liver diseases is scarce, with distinct lifestyle, genetic factors, fat distribution and hepatitis B virus (HBV) infection from Western populations. This study aimed to explore this association, examine the modifying effects of midlife healthy lifestyle factors (HLFs) and hepatitis B surface antigen (HBsAg) status on this association, and evaluate the mediating effect of midlife metabolic syndrome (MetS).Methods: This prospective cohort study utilized data from the China Kadoorie Biobank (CKB), enrolling adults aged 35–70 years free of baseline cancer or liver disease. A total of 387,541 participants from ten Chinese regions were included in the analysis. Primary outcomes were morbidity of chronic liver disease (CLD), metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD), which were obtained mainly through local disease and death registries and the national health insurance (HI) system. Weight at age 25, midlife lifestyle and HBsAg status were obtained from the CKB baseline survey. Cox proportional hazards models were applied to estimate the association between early adulthood BMI and later-life liver-related outcomes. Interaction analysis was performed to examine the modifying effects of midlife HLF and HBsAg status. The Bootstrap method was used to verify the mediation effect of MetS in the association under investigation.Findings: The baseline survey was conducted from 2004 to 2008. During a median follow-up of 12·1 years 5,983 (1·5%) incident CLD cases were documented. After adjustment for covariates, elevated early-adulthood BMI was associated with increased later-life CLD risk in a monotonic dose-response manner (P for trend 0·05), whereas HBsAg status exhibited a significant interaction with early adulthood BMI (P = 0·008), and in the HBsAg-negative group, later-life CLD risk was positively associated with early adulthood BMI. MetS-mediated effect was strongest for MASLD, the proportion mediated increased from 20·71% to 46·74% with rising BMI (all P < 0·001).Interpretation: This study confirms that higher BMI in early adulthood significantly increases the risk of later-life chronic liver diseases among Chinese adults, particularly in HBsAg-negative adults, regardless of subsequent lifestyle changes. These findings highlight the urgency for public health strategies to prevent overweight in young adulthood and to optimize the management of HBV infection.
- 30 October 2025
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (1) , 69-82
Global, regional, and national burden and trends of liver cancer due to hepatitis B in young adults from 1990 to 2021 and forecast to 2030: insights from the Global Burden of Disease Study 2021
Liver cancer due to hepatitis B (LCHB) presents a major public health challenge, particularly in younger populations. To date, comprehensive analyses of the global burden and changing trends of LCHB in young adults aged 15–49 years are understudied. We collected prevalence, mortality, and disability-adjusted life years (DALYs) between 1990 and 2021 from the Global Burden of Disease (GBD) Study 2021. Percentage change and estimated annual percentage change (EAPC) were calculated to quantify temporal trends. The future burden to 2030 was projected using the Bayesian age-period-cohort (BAPC) model. From 1990 to 2021, the global prevalence, mortality, and DALYs cases of LCHB in young adults increased by 49.72%, 18.70%, and 16.08%, while the age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) declined, with EAPCs of − 0.66%, − 1.49%, and − 1.54%, respectively. The sex ratio remained consistent at 5:1 (male to female). The middle and high-middle SDI regions bore heavier burden than other SDI regions. In 2021, East Asia recorded the highest cases and age-standardized rate of prevalence, mortality, and DALYs. The younger age groups exhibited lower disease burden compared to older ones. New case numbers are predicted to increase globally, particularly in China. While the absolute cases of prevalence, mortality, and DALYs for LCHB in young adults have increased globally, the ASPR, ASMR, and ASDR have declined over the past 32 years. Temporal trend varied by region, country, sex, and age group, with the global burden expected to present ongoing challenges.
- 30 October 2025
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (1) , 69-82
Global, regional, and national burden and trends of liver cancer due to hepatitis B in young adults from 1990 to 2021 and forecast to 2030: insights from the Global Burden of Disease Study 2021
Liver cancer due to hepatitis B (LCHB) presents a major public health challenge, particularly in younger populations. To date, comprehensive analyses of the global burden and changing trends of LCHB in young adults aged 15–49 years are understudied. We collected prevalence, mortality, and disability-adjusted life years (DALYs) between 1990 and 2021 from the Global Burden of Disease (GBD) Study 2021. Percentage change and estimated annual percentage change (EAPC) were calculated to quantify temporal trends. The future burden to 2030 was projected using the Bayesian age-period-cohort (BAPC) model. From 1990 to 2021, the global prevalence, mortality, and DALYs cases of LCHB in young adults increased by 49.72%, 18.70%, and 16.08%, while the age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) declined, with EAPCs of − 0.66%, − 1.49%, and − 1.54%, respectively. The sex ratio remained consistent at 5:1 (male to female). The middle and high-middle SDI regions bore heavier burden than other SDI regions. In 2021, East Asia recorded the highest cases and age-standardized rate of prevalence, mortality, and DALYs. The younger age groups exhibited lower disease burden compared to older ones. New case numbers are predicted to increase globally, particularly in China. While the absolute cases of prevalence, mortality, and DALYs for LCHB in young adults have increased globally, the ASPR, ASMR, and ASDR have declined over the past 32 years. Temporal trend varied by region, country, sex, and age group, with the global burden expected to present ongoing challenges.
- Open Access
- 16 October 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1666408
Global burden of HIV, syphilis, and HBV infection among women of childbearing age and children under five: based on the Global Burden of Diseases Study 2021
Introduction: Human immunodeficiency virus (HIV), syphilis, and hepatitis B virus (HBV) infection pose a major global public health challenge. However, high-quality integrated data on the burden of these diseases among women of childbearing age (WCBA) and children remain limited. This study aims to provide a comprehensive global assessment of HIV, syphilis, and HBV infection among WCBA and children under five and to explore their potential relationships.Methods: The Global Burden of Disease Study 2021 provided data on the global prevalence of WCBA and incidence of HIV, syphilis, and HBV infection in children under five years old from 1990 to 2021. Temporal trends were analyzed using annual average percentage change (AAPC) and joinpoint regression. A Bayesian age-period-cohort model was used to forecast the disease burden from 2022 to 2030.Results: In 2021, the age-standardized prevalence (ASPR) of HIV infection among WCBA was 830.87 per 100,000, while the age-standardized incidence (ASIR) of HIV among children under five was 15.39 per 100,000. From 1990 to 2021, the ASPR of HIV in WCBA demonstrated sustained growth, whereas the ASIR in children exhibited a rise-then-fall pattern. For syphilis, the 2021 ASPR among WCBA was 1057.32 per 100,000, and the ASIR in children was 58.36 per 100,000; both metrics followed a declining-then-rising trend, returning to 1990 levels by 2021. Both the ASPR of HBV infection among WCBA and the ASIR among children under five declined significantly from 1990 to 2021, with average annual percentage changes of −1.25% and −4.14%, respectively. Generally, ASPR and ASIR decreased as the sociodemographic index (SDI) increased. Regions with lower SDI experienced a disproportionately higher burden of HIV, syphilis, and HBV infections.Conclusion: In 2021, the global disease burden of HIV, syphilis, and HBV infection remained high among WCBA and children under five, with significant regional and demographic disparities. These findings indicate a persistent public health challenge, necessitating continued global efforts to mitigate the burden through addressing socioeconomic inequalities, strengthening health education, and expanding healthcare access.
- 16 October 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1666408
Open AccessGlobal burden of HIV, syphilis, and HBV infection among women of childbearing age and children under five: based on the Global Burden of Diseases Study 2021
Introduction: Human immunodeficiency virus (HIV), syphilis, and hepatitis B virus (HBV) infection pose a major global public health challenge. However, high-quality integrated data on the burden of these diseases among women of childbearing age (WCBA) and children remain limited. This study aims to provide a comprehensive global assessment of HIV, syphilis, and HBV infection among WCBA and children under five and to explore their potential relationships.Methods: The Global Burden of Disease Study 2021 provided data on the global prevalence of WCBA and incidence of HIV, syphilis, and HBV infection in children under five years old from 1990 to 2021. Temporal trends were analyzed using annual average percentage change (AAPC) and joinpoint regression. A Bayesian age-period-cohort model was used to forecast the disease burden from 2022 to 2030.Results: In 2021, the age-standardized prevalence (ASPR) of HIV infection among WCBA was 830.87 per 100,000, while the age-standardized incidence (ASIR) of HIV among children under five was 15.39 per 100,000. From 1990 to 2021, the ASPR of HIV in WCBA demonstrated sustained growth, whereas the ASIR in children exhibited a rise-then-fall pattern. For syphilis, the 2021 ASPR among WCBA was 1057.32 per 100,000, and the ASIR in children was 58.36 per 100,000; both metrics followed a declining-then-rising trend, returning to 1990 levels by 2021. Both the ASPR of HBV infection among WCBA and the ASIR among children under five declined significantly from 1990 to 2021, with average annual percentage changes of −1.25% and −4.14%, respectively. Generally, ASPR and ASIR decreased as the sociodemographic index (SDI) increased. Regions with lower SDI experienced a disproportionately higher burden of HIV, syphilis, and HBV infections.Conclusion: In 2021, the global disease burden of HIV, syphilis, and HBV infection remained high among WCBA and children under five, with significant regional and demographic disparities. These findings indicate a persistent public health challenge, necessitating continued global efforts to mitigate the burden through addressing socioeconomic inequalities, strengthening health education, and expanding healthcare access.
- 18 June 2025
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 90, 127688
Mediating role of whole epigenome DNA methylation signatures in the association between copper and SGA
- 18 June 2025
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 90, 127688
Mediating role of whole epigenome DNA methylation signatures in the association between copper and SGA
- Open Access
- 6 June 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-15
Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021
The issue of breast cancer in young women (BCYW) has gained increasing attention over the past few decades. However, a notable gap exists in the literature concerning the comparison of the disease burden of BCYW with that of other age groups. This study presents a comprehensive analysis of the disparities in global, regional, and national burden between BCYW and their middle-aged and elderly counterparts. The breast cancer data in this study were collected from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021). The age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), age-standardized prevalence rate (ASPR), and age-standardized disability-adjusted life years rate (ASDR), and the Average Annual Percent Change (AAPC) were employed to assess the disease burden of BCYW. The Bayesian Age-Period-Cohort model was used to forecast disease burden from 2022 to 2030. The AAPC of ASIR of BCYW from 1990 to 2021 was 0.91 (95% CI: 0.77 to 1.05), exceeding the global average (0.49, 95% CI: 0.40 to 0.58) as well as both middle-aged (0.60, 95% CI: 0.47 to 0.73) and elderly groups (0.30, 95% CI: 0.21 to 0.39). The AAPC for ASMR of BCYW experienced a marginal increase of 0.02 (95%CI: -0.07 to 0.11) from 1990 to 2021, surpassing the rates observed in both the middle-aged group (-0.40, 95%CI: -0.47 to -0.32) and the elderly group (-0.50, 95%CI: -0.62 to -0.38). The ASIR in BCYW significantly increased in regions with low (AAPC = 1.87), low-middle (AAPC = 2.32), middle (AAPC = 1.84), and high-middle SDI (AAPC = 0.98), while it remained unchanged in regions with high SDI (AAPC = -0.02). This trend was also observed among middle-aged and older groups. The ASMR in BCYW significantly increased in regions with low (AAPC = 1.01) and low-middle SDI (AAPC = 1.25), but remained unchanged in regions with middle SDI (AAPC = 0.02), while it decreased in regions with high-middle (AAPC = -1.10) and high SDI (AAPC = -1.60). Among the middle-aged and elderly populations, there was an increase in ASMR rates observed in regions with low, low-middle, and middle SDI groups (all AAPC > 0), whereas a decrease was noted in the regions with high-middle and high SDI (all AAPC < 0). The BAPC predicts a consistent annual increase in ASIR, ASMR, ASPR, and ASDR of BCYW globally and in China from 2022 to 2030. Notably, China has higher ASIR and ASPR rates compared to the global average, while its ASMR and ASDR rates are lower. The burden of BCYW was particularly significant in regions with low-SDI, low-middle SDI, and middle SDI. Despite the progress made, China still faces considerable challenges in effectively addressing this issue. The prevention and control of BCYW must remain a priority. Different countries and regions should develop personalized, targeted intervention strategies for this population and establish public health policies tailored to the specific needs of each region.
- 6 June 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-15
Open AccessGlobal, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021
The issue of breast cancer in young women (BCYW) has gained increasing attention over the past few decades. However, a notable gap exists in the literature concerning the comparison of the disease burden of BCYW with that of other age groups. This study presents a comprehensive analysis of the disparities in global, regional, and national burden between BCYW and their middle-aged and elderly counterparts. The breast cancer data in this study were collected from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021). The age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), age-standardized prevalence rate (ASPR), and age-standardized disability-adjusted life years rate (ASDR), and the Average Annual Percent Change (AAPC) were employed to assess the disease burden of BCYW. The Bayesian Age-Period-Cohort model was used to forecast disease burden from 2022 to 2030. The AAPC of ASIR of BCYW from 1990 to 2021 was 0.91 (95% CI: 0.77 to 1.05), exceeding the global average (0.49, 95% CI: 0.40 to 0.58) as well as both middle-aged (0.60, 95% CI: 0.47 to 0.73) and elderly groups (0.30, 95% CI: 0.21 to 0.39). The AAPC for ASMR of BCYW experienced a marginal increase of 0.02 (95%CI: -0.07 to 0.11) from 1990 to 2021, surpassing the rates observed in both the middle-aged group (-0.40, 95%CI: -0.47 to -0.32) and the elderly group (-0.50, 95%CI: -0.62 to -0.38). The ASIR in BCYW significantly increased in regions with low (AAPC = 1.87), low-middle (AAPC = 2.32), middle (AAPC = 1.84), and high-middle SDI (AAPC = 0.98), while it remained unchanged in regions with high SDI (AAPC = -0.02). This trend was also observed among middle-aged and older groups. The ASMR in BCYW significantly increased in regions with low (AAPC = 1.01) and low-middle SDI (AAPC = 1.25), but remained unchanged in regions with middle SDI (AAPC = 0.02), while it decreased in regions with high-middle (AAPC = -1.10) and high SDI (AAPC = -1.60). Among the middle-aged and elderly populations, there was an increase in ASMR rates observed in regions with low, low-middle, and middle SDI groups (all AAPC > 0), whereas a decrease was noted in the regions with high-middle and high SDI (all AAPC < 0). The BAPC predicts a consistent annual increase in ASIR, ASMR, ASPR, and ASDR of BCYW globally and in China from 2022 to 2030. Notably, China has higher ASIR and ASPR rates compared to the global average, while its ASMR and ASDR rates are lower. The burden of BCYW was particularly significant in regions with low-SDI, low-middle SDI, and middle SDI. Despite the progress made, China still faces considerable challenges in effectively addressing this issue. The prevention and control of BCYW must remain a priority. Different countries and regions should develop personalized, targeted intervention strategies for this population and establish public health policies tailored to the specific needs of each region.
- Open Access
- 23 April 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1526053
Effects of folic acid supplementation before conception on innate immunity and anti-HBs levels of offspring born to HBsAg-positive mothers
Introduction: Folic acid has been associated with fetal development, especially in fetal immunity. Therefore, limited evidence regarding the effects of different folic acid supplementation of hepatitis B surface antigen (HBsAg) positive mothers in innate immunity in offspring. Herein, this study aimed to explore the association between folic acid supplementation and the innate immunity of neonates and the immunological efficacy of hepatitis B vaccine (HepB), which may provide insights that could inform pre-pregnancy health management in HBsAg-positive mothers.Materials and methods: It is an ambispective cohort study with 293 pairs of HBsAg-positive mothers-offspring in Taiyuan, Shanxi Province, China. Mothers were classified into three groups according to the time of starting folic acid supplementation, non-supplementation group, pre-pregnancy group and post-pregnancy supplementation group. Immunological indexes such as immune cells proportion and innate immune mediators in cord blood and anti-HBs in infants were measured. Differences in immunological indexes were analyzed by One-Way ANOVA test. Univariate and multivariate analyses were performed for factors associated with abnormal immunological indexes and potential confounders were adjusted.Results: The preconception folic acid group showed a significantly higher expression levels of STING (P = 0.005) and pNF-κB (P = 0.010) in cord blood along with higher anti-HBs titres (P = 0.006), when compared to both non-supplementation group and post-pregnancy supplementation group. Higher anti-HBs levels indicate a stronger immune response to HepB and may enhance protection against HBV infection during early life. Infants in the high pNF-κB expression group exhibited a significantly elevated seropositive rate of HepB compared to those in the low pNF-κB expression group (P = 0.037). There were no mediation effects and no moderation effects in this study, potentially due to the direct influence of folic acid supplementation on immune responses or the limited sample size.Discussion: In conclusion, our findings demonstrate that preconception folic acid supplementation may enhance HepB vaccine responsiveness in infants of HBsAg-positive mothers. Meanwhile, high pNF-κB expression in cord blood can increase seropositive rates in infants. This discovery has significant public health implications, as it may provide a simple and accessible intervention to improve vaccination outcomes and reduce HBV transmission in endemic regions.
- 23 April 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1526053
Open AccessEffects of folic acid supplementation before conception on innate immunity and anti-HBs levels of offspring born to HBsAg-positive mothers
Introduction: Folic acid has been associated with fetal development, especially in fetal immunity. Therefore, limited evidence regarding the effects of different folic acid supplementation of hepatitis B surface antigen (HBsAg) positive mothers in innate immunity in offspring. Herein, this study aimed to explore the association between folic acid supplementation and the innate immunity of neonates and the immunological efficacy of hepatitis B vaccine (HepB), which may provide insights that could inform pre-pregnancy health management in HBsAg-positive mothers.Materials and methods: It is an ambispective cohort study with 293 pairs of HBsAg-positive mothers-offspring in Taiyuan, Shanxi Province, China. Mothers were classified into three groups according to the time of starting folic acid supplementation, non-supplementation group, pre-pregnancy group and post-pregnancy supplementation group. Immunological indexes such as immune cells proportion and innate immune mediators in cord blood and anti-HBs in infants were measured. Differences in immunological indexes were analyzed by One-Way ANOVA test. Univariate and multivariate analyses were performed for factors associated with abnormal immunological indexes and potential confounders were adjusted.Results: The preconception folic acid group showed a significantly higher expression levels of STING (P = 0.005) and pNF-κB (P = 0.010) in cord blood along with higher anti-HBs titres (P = 0.006), when compared to both non-supplementation group and post-pregnancy supplementation group. Higher anti-HBs levels indicate a stronger immune response to HepB and may enhance protection against HBV infection during early life. Infants in the high pNF-κB expression group exhibited a significantly elevated seropositive rate of HepB compared to those in the low pNF-κB expression group (P = 0.037). There were no mediation effects and no moderation effects in this study, potentially due to the direct influence of folic acid supplementation on immune responses or the limited sample size.Discussion: In conclusion, our findings demonstrate that preconception folic acid supplementation may enhance HepB vaccine responsiveness in infants of HBsAg-positive mothers. Meanwhile, high pNF-κB expression in cord blood can increase seropositive rates in infants. This discovery has significant public health implications, as it may provide a simple and accessible intervention to improve vaccination outcomes and reduce HBV transmission in endemic regions.
- 6 February 2025
- Published by Elsevier in Immunology Letters
- Vol. 272, 106977
In virto priming of the STING signaling pathway enhances the maturation and activation of dendritic cells induced by hepatitis B vaccine
- 6 February 2025
- Published by Elsevier in Immunology Letters
- Vol. 272, 106977
In virto priming of the STING signaling pathway enhances the maturation and activation of dendritic cells induced by hepatitis B vaccine